

# Online Supplement for: Optimal Coinsurance Rates for a Heterogeneous Population under Inequality and Resource Constraints

Greggory J. Schell<sup>1</sup>, Gian-Gabriel P. Garcia<sup>2</sup>, Mariel S. Lavieri<sup>2</sup>, Jeremy B. Sussman<sup>3</sup>,  
Rodney A. Hayward<sup>3</sup>

<sup>1</sup>*Center for Naval Analyses, 3003 Washington Blvd, Arlington, VA 22201, USA*

<sup>2</sup>*Industrial and Operations Engineering, University of Michigan, 1205 Beal Ave, Ann Arbor, MI 48109, USA*

<sup>3</sup>*Center for Clinical Management Research, Ann Arbor Veterans Affairs Hospital, 2215 Fuller Road, Ann Arbor, MI 48105, USA*

schellg@cna.org, garciagg@umich.edu, lavieri@umich.edu, jeremysu@med.umich.edu,  
rhayward@med.umich.edu

## A Model Parameters for Additional Applications

The table below provides the parameters used in the additional applications which considered medium-intensity statins, high-intensity statins, and PCSK9 inhibitors as cholesterol-lowering treatments for cardiovascular risk reduction. Parameters which were identical to the hypertension application in the main paper are not shown.

Table A1: Coinsurance BLP inputs and data sources. All costs reported are in 2015 USD after using appropriate cumulative inflation rates, e.g. 9.9% for 2008 to 2015.

Input	Value	Source
Risk calculator for cholesterol applications	ASCVD	(Preiss and Kristensen 2015)
Treatment benefit for statins	Relative risk reduction	(Baigent et al. 2005)
Treatment benefit for PCSK9 inhibitors	Relative risk reduction	(Kazi et al. 2016)
Annual cost of medium-intensity statins	\$582	Drugs.com
Annual cost of high-intensity statins	\$611	Drugs.com
Annual cost of PCSK9 inhibitors	\$14350	(Kazi et al. 2016)
Disutility for medium-intensity statins $d_{MS}(\mathbf{s})$	0.001	(Hayward et al. 2010)
Disutility for high-intensity statins $d_{HS}(\mathbf{s})$	0.002	(Hayward et al. 2010)
Disutility for PCSK9 inhibitors $d_{PI}(\mathbf{s})$	0.0025	(Kazi et al. 2016)

## References

Drugs.com. <https://www.drugs.com/>. Accessed: 2017-04-12.

Baigent, C., Keech, A., Kearney, P. M., and Blackwell, L. (2005). Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. *The Lancet*, 366:1267–1278.

Hayward, R. A., Krumholz, H. M., Zulman, D. M., Timbie, J. W., and Vijan, S. (2010). Optimizing Statin Treatment for Primary Prevention of Coronary Artery Disease. *Annals of Internal Medicine*, 152:69–77.

Kazi, D. S., Moran, A. E., Coxson, P. G., Penko, J., Ollendorf, D. A., Pearson, S. D., Tice, J. A., Guzman, D., and Bibbins-Domingo, K. (2016). Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. *Journal of the American Medical Association*, 316(7):743–753.

Preiss, D. and Kristensen, S. L. (2015). The new pooled cohort equations risk calculator. *Canadian Journal of Cardiology*, 31(5):613–619.